Moonlake’s FDA Alignment Sets Up a Key BLA Catalyst for MLTX Investors
Moonlake reports no remaining FDA gaps, putting an expected November 29 BLA acceptance date at the center of the MLTX regulatory story.
J&J’s Rybrevant Approval Adds a New Oncology Catalyst for Investors
Johnson & Johnson’s accelerated FDA approval for Rybrevant strengthens its oncology pipeline and puts regulatory execution back in focus.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Xeris’ Recorlev Ambition Pulls Forward Revenue Case as XERS Nears Seven-Year Highs
Xeris’ earlier Recorlev sales ambition gives XERS a sharper growth narrative, but clinical milestones and execution risk…
Viatris Stock Gains 1.6% as Q3 Results Put $19.51 Breakout in Focus
Viatris shares rose 1.6% after Q3 results, putting the $19.51 breakout level and prior FDA approval in focus for traders…
ANI Pharmaceuticals’ $560 Million Egetis Deal Signals Renewed Rare-Disease M&A Momentum
ANI Pharmaceuticals’ reported $560 million Egetis acquisition would expand its rare-disease portfolio and underscore cro…
Agenus Posts Q3 Profit as Phase 3 Colon Cancer Trial Moves Forward
Agenus reported a Q3 profit while advancing its Phase 3 colon cancer trial, giving investors a fresh catalyst to weigh a…
Novavax Narrows Q3 Loss as Sanofi Partnership Delivers $125 Million Milestone
Novavax posted a $31 million Q3 loss as a Sanofi-linked milestone payment offset a 3% revenue decline to $68 million.
Rhythm Pharmaceuticals Jumps on Reported $10 Billion AstraZeneca Bid
A reported $10 billion AstraZeneca bid sent Rhythm Pharmaceuticals shares higher and could reset expectations for rare-d…
Rapport Therapeutics’ $815 Million Cash Position Sets Up a Catalyst-Heavy End to 2026
Rapport’s $815.4 million cash balance and coming epilepsy data put its Phase 3 program at the center of investor attenti…
Ultragenyx Faces a Gene-Therapy Growth Test After Two FDA Approvals and Workforce Cuts
Ultragenyx’s two FDA-approved gene therapies mark a commercial shift, but Q3 revenue of $173 million came with a $118 mi…
GRAIL Stock Nears 52-Week High as FDA Panel Backs Cancer Detection Test Ahead of Earnings
GRAIL shares stand near their 52-week high as an FDA panel backs its cancer test and earnings approach, setting up two p…